Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CHYM vs AMBQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHYM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

CHYM Overall Winner 6-Pillar Tally: CHYM 4 – 2 AMBQ Matrix Metrics: CHYM 8 – 2 AMBQ

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Ambiq Micro, Inc. (AMBQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHYM carries a Unified Composite Score of 27.2/100 (SELL) at $34.48 (30.9x Forward P/E, 19.3% operating margin), whereas AMBQ carries 46.9/100 (HOLD) at $44.59 (N/M Forward P/E, -36.0% operating margin).

  • Composite vs. Pillar Nuance: While AMBQ currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. CHYM 27.2/100 SELL), CHYM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -36.0% operating margin) and revenue trajectory (+32.1% vs. +110.0% YoY).
  • Technical & Structure Timing Caution: CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.6); meanwhile AMBQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHYM vs AMBQ
CHYM NASDAQ Head-to-Head Winner
Chime Financial, Inc. Class A Common Stock
Finance Services
$34.48
+2.77% 1D
Market Cap $12.7B
TTM Revenue $14.3B
Forward P/E 30.9x
Beta / 30D Vol 1.45β · 36% Vol
Unified Composite Score
27.2 / 100 SELL
Tech 15.0 Fund 33.0 Flow 57.0 Mom 30.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 74
RSI-14: 73.6 · SMA20: $30.53 · SMA50: $29.95
AMBQ NYSE
Ambiq Micro, Inc.
Semiconductors & Related Devices
$44.59
-6.05% 1D
Market Cap $1.2B
TTM Revenue $118M
Forward P/E N/M
Beta / 30D Vol 3.71β · 125% Vol
Unified Composite Score
46.9 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.4%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $47.52 · SMA50: $56.35

6-Pillar Scorecard Institutional Category Breakdown (CHYM 4 – 2 AMBQ)

Columns: Metric · CHYM · AMBQ
1. Valuation Multiples CHYM
Forward P/E 30.9x N/M
Trailing P/E 29.0x N/M
PEG Ratio N/M N/M
EV / Revenue 0.7x 7.3x
2. Growth & Scale AMBQ
Revenue Growth (YoY) +32.1% +110.0%
Earnings Growth (YoY) -33.8% +0.0%
TTM Revenue (USD) $14.3B $118M
Market Cap $12.7B $1.2B
3. Profitability & Quality CHYM
Gross Margin 89.4% 44.8%
Operating Margin 19.3% -36.0%
Net Profit Margin 3.0% -29.7%
Return on Equity (ROE) 5.4% -12.2%
4. Balance Sheet & Cash Flow CHYM
Cash Generation (TTM) $2.27B -$40M
Cash Flow Margin 15.8% -33.8%
Net Cash / Leverage $2.77B Net Cash $359M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CHYM
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 50.0% (15th %ile) 96.5% (27th %ile)
Put/Call OI Skew 0.22x (Call-Skewed) 2.14x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AMBQ
OpEx & R&D Intensity 70.1% of Rev ($10.1B) 80.8% of Rev ($95M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Semiconductors Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHYM (8) vs AMBQ (2)
Institutional Metric CHYM AMBQ Criterion Row Edge
Market Capitalization
Scale
$12.7B $1.2B Larger Scale CHYM
Trailing P/E Ratio
Valuation
29.0x N/M Lower Multiple CHYM
Forward P/E Ratio
Valuation
30.9x N/M Lower Multiple CHYM
Revenue Growth (YoY)
Growth
+32.1% +110.0% Higher Growth AMBQ
Operating Margin (TTM)
Profitability
19.3% -36.0% Higher Margin CHYM
Net Profit Margin
Profitability
3.0% -29.7% Higher Margin CHYM
Return on Equity (ROE)
Capital Efficiency
5.4% -12.2% Higher ROE CHYM
52-Week Range Position
Momentum
95% ($16–$36) 32% ($22–$92) Stronger Trend CHYM
Beta / 30D Volatility
Risk Regime
1.45β · 36% Vol 3.71β · 125% Vol Lower Realized Risk CHYM
Unified Institutional Score
Composite Signal
27.2 / 100 (SELL) 46.9 / 100 (HOLD) Higher Composite AMBQ
Trailing 12M Revenue (USD)
Operating Scale
$14.3B $118M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.4% 44.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.7x EV/Rev N/M PEG · 7.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.27B ($2.77B Net Cash) -$40M ($359M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHYM +26.82 pp
CHYM: +16.21% · AMBQ: -10.61%
3M Horizon CHYM +37.28 pp
CHYM: +8.05% · AMBQ: -29.23%
6M Horizon CHYM +133.97 pp
CHYM: +96.47% · AMBQ: -37.5%
1Y Horizon CHYM +7.32 pp
CHYM: +79.68% · AMBQ: +72.36%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CHYM Revenue AMBQ Revenue CHYM Op. Margin AMBQ Op. Margin Margin Leader
FY2023 $1.28B N/A -18.4% N/A CHYM
FY2024 $1.67B $80M -3.7% -53.4% CHYM
FY2025 $2.19B $70M -47.6% -54.5% CHYM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHYM CONSOLIDATION
48d in phase · OBV ACCUMULATION
Current IV 50.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact CHYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AMBQ BREAKDOWN
104d in phase · OBV NEUTRAL
Current IV 96.5%
IV Percentile 27th %ile
Put/Call OI Skew 2.14x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AMBQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHYM Moat Profile Scale & Operating Efficiency Moat
Software - Application Operator
Competes within the Software - Application value chain with $12.7B market capitalization and 19.3% operating margin.
OpEx & R&D Reinvestment 70.1% of Rev ($10.1B)
90D Engineering Disclosures 0 Published
AMBQ Moat Profile Cyclical / Execution-Driven Positioning
Semiconductors Operator
Competes within the Semiconductors value chain with $1.2B market capitalization and -36.0% operating margin.
OpEx & R&D Reinvestment 80.8% of Rev ($95M)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (15 partners):
Taiwan Semiconductor Manufacturing Company ARM Holdings Synopsys Cadence Design Systems

Investor FAQ CHYM vs AMBQ Key Questions & Quantitative Answers

As of Nov 16, 2026, Chime Financial, Inc. (CHYM) is the stronger overall head-to-head candidate over Ambiq Micro, Inc. (AMBQ) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHYM carries a Unified Composite Score of 27.2/100 (SELL) at $34.48 (30.9x Forward P/E, 19.3% operating margin), whereas AMBQ carries 46.9/100 (HOLD) at $44.59 (N/M Forward P/E, -36.0% operating margin). Composite vs. Pillar Nuance: While AMBQ currently prints a higher short-term Unified Composite Score (46.9/100 HOLD vs. CHYM 27.2/100 SELL), CHYM captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (19.3% vs. -36.0% operating margin) and revenue trajectory (+32.1% vs. +110.0% YoY). Technical & Structure Timing Caution: CHYM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 73.6); meanwhile AMBQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMBQ leads the Growth & Scale pillar: CHYM posts +32.1% YoY revenue growth and -33.8% YoY earnings growth on $14.3B TTM revenue (89.4% gross margin, 19.3% operating margin), compared with AMBQ at +110.0% YoY revenue growth and +0.0% YoY earnings growth on $118M TTM revenue (44.8% gross margin, -36.0% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), CHYM cumulative revenue shifted +71.1% while AMBQ shifted -12.5%. In operating R&D and SG&A reinvestment, CHYM deploys 70.1% of Rev ($10.1B) (0 90-day corporate R&D disclosures) versus 80.8% of Rev ($95M) (0 disclosures) for AMBQ.

CHYM screens cheaper on headline valuation multiples. CHYM trades at 30.9x Forward P/E, 29.0x Trailing P/E, N/M PEG, and 0.7x EV/Revenue (15.8% FCF margin), whereas AMBQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.3x EV/Revenue (-33.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHYM (5.4% ROE) versus AMBQ (-12.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CHYM carries 50.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.45β · 36% Vol realized risk). By comparison, AMBQ carries 96.5% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 2.14x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.71β · 125% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.